The investigators want to investigate if HIV sero-positive males benefit from vitamin D supplementation. The study runs in 16 weeks and the participants are treated with one of three placebo controlled regimes (tablets): 1. Calcium 2. Calcium and 25-hydroxy-vitamin D 3. Calcium and 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D The endpoints are: * Serum vitamin D * Parathyroid hormone * ionized calcium * T-lymphocyte fractions (naïve, mature, Tregs) * Osteocalcin (bone metabolism)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
Dept. of endocrinology, Hvidovre Hospital
Copenhagen, Denmark
serum-vitamin D metabolites
Time frame: week 0
serum-vitamin D metabolites
Time frame: week 2
serum-vitamin D metabolites
Time frame: week 4
serum-vitamin D metabolites
Time frame: week 8
serum-vitamin D metabolites
Time frame: week 12
serum-vitamin D metabolites
Time frame: week 16
T-lymphocyte fractions Parathyroid hormone ionized calcium
Time frame: week 0
T-lymphocyte fractions Parathyroid hormone ionized calcium
Time frame: week 2
T-lymphocyte fractions Parathyroid hormone ionized calcium
Time frame: week 4
T-lymphocyte fractions Parathyroid hormone ionized calcium
Time frame: week 8
T-lymphocyte fractions Parathyroid hormone ionized calcium
Time frame: week 12
T-lymphocyte fractions Parathyroid hormone ionized calcium
Time frame: week 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.